Market Research Logo

Esophageal Cancer - Pipeline Review, H2 2016

Esophageal Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Esophageal Cancer - Pipeline Review, H2 2016’, provides an overview of the Esophageal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
    • The report reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects
    • The report assesses Esophageal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Esophageal Cancer
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Esophageal Cancer Overview
    Therapeutics Development
    Pipeline Products for Esophageal Cancer - Overview
    Pipeline Products for Esophageal Cancer - Comparative Analysis
    Esophageal Cancer - Therapeutics under Development by Companies
    Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes
    Esophageal Cancer - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Esophageal Cancer - Products under Development by Companies
    Esophageal Cancer - Products under Investigation by Universities/Institutes
    Esophageal Cancer - Companies Involved in Therapeutics Development
    Adaptimmune Therapeutics Plc
    Advaxis, Inc.
    Advenchen Laboratories, LLC
    Almac Discovery Limited
    Amgen Inc.
    ArQule, Inc.
    Array BioPharma Inc.
    Aslan Pharmaceuticals Pte. Ltd.
    ATLAB Pharma SAS
    Bayer AG
    Betta Pharmaceuticals Co. Ltd.
    Boehringer Ingelheim GmbH
    Celgene Corporation
    Celldex Therapeutics, Inc.
    Cellectar Biosciences, Inc.
    Cerulean Pharma, Inc.
    Cyclacel Pharmaceuticals, Inc.
    F. Hoffmann-La Roche Ltd.
    Genmab A/S
    GlaxoSmithKline Plc
    Glycotope GmbH
    Hutchison MediPharma Limited
    Ignyta, Inc.
    ImmunoFrontier, Inc.
    Immunomedics, Inc.
    Johnson & Johnson
    Komipharm International Co., Ltd.
    MacroGenics, Inc.
    MaxiVAX SA
    Mebiopharm Co., Ltd.
    MedImmune, LLC
    Merck & Co., Inc.
    Mirna Therapeutics, Inc.
    Novartis AG
    Omeros Corporation
    Omnitura Therapeutics Inc.
    Oncolys BioPharma Inc
    OncoMed Pharmaceuticals, Inc.
    Ono Pharmaceutical Co., Ltd.
    Pfizer Inc.
    Proteo, Inc.
    Puma Biotechnology, Inc.
    Rhizen Pharmaceuticals S.A.
    Shionogi & Co., Ltd.
    Spectrum Pharmaceuticals, Inc.
    Symphogen A/S
    Taiho Pharmaceutical Co., Ltd.
    Taiwan Liposome Company, Ltd.
    Takara Bio Inc.
    Transgene Biotek Limited
    VioQuest Pharmaceuticals, Inc.
    XuanZhu Pharma Co., Ltd.
    Esophageal Cancer - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (tipiracil hydrochloride + trifluridine) - Drug Profile
    1-BB1 - Drug Profile
    ADXS-HER2 - Drug Profile
    afatinib dimaleate - Drug Profile
    AL-3818 - Drug Profile
    ALM-301 - Drug Profile
    alpelisib - Drug Profile
    AMG-337 - Drug Profile
    apatinib - Drug Profile
    atezolizumab - Drug Profile
    ATL-101 - Drug Profile
    binimetinib - Drug Profile
    brontictuzumab - Drug Profile
    CDX-1401 - Drug Profile
    Cellular Immunotherapy for Oncology - Drug Profile
    Cellular Immunotherapy for Oncology - Drug Profile
    Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile
    Cellular Immunotherapy to Target NY-ESO-1 for Oncology - Drug Profile
    cetuximab biobetter - Drug Profile
    CGX-1321 - Drug Profile
    CRLX-101 - Drug Profile
    CYC-140 - Drug Profile
    DKN-01 - Drug Profile
    donafenib - Drug Profile
    durvalumab - Drug Profile
    elgemtumab - Drug Profile
    erdafitinib - Drug Profile
    futuximab - Drug Profile
    ganetespib - Drug Profile
    gedatolisib - Drug Profile
    GSK-2256098 - Drug Profile
    GSK-3377794 - Drug Profile
    HMPL-309 - Drug Profile
    I131-CLR1404 - Drug Profile
    icotinib hydrochloride - Drug Profile
    IMF-001 - Drug Profile
    JS-001 - Drug Profile
    KML-001 - Drug Profile
    margetuximab - Drug Profile
    MBP-426 - Drug Profile
    miR-215 - Drug Profile
    MMD-37K - Drug Profile
    Monoclonal Antibodies to Inhibit PD-L2 for Esophageal Cancer - Drug Profile
    MVXONCO-1 - Drug Profile
    neratinib - Drug Profile
    nimotuzumab - Drug Profile
    nintedanib - Drug Profile
    nivolumab - Drug Profile
    OBP-301 - Drug Profile
    OMN-54 - Drug Profile
    paclitaxel albumin bound - Drug Profile
    panitumumab - Drug Profile
    pasireotide ER - Drug Profile
    PCA-062 - Drug Profile
    pembrolizumab - Drug Profile
    pralatrexate - Drug Profile
    RXDX-106 - Drug Profile
    S-222611 - Drug Profile
    S-588410 - Drug Profile
    sacituzumab - Drug Profile
    SDS-eCAR - Drug Profile
    sirotinib - Drug Profile
    Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile
    Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile
    SMYD-2BAY02 - Drug Profile
    TBI-1201 - Drug Profile
    TBL-0805E - Drug Profile
    TGR-1202 - Drug Profile
    tiprelestat - Drug Profile
    tisotumab vedotin - Drug Profile
    tivantinib - Drug Profile
    TLC-388 - Drug Profile
    triciribine phosphate - Drug Profile
    Vaccine for Esophageal Cancer and Colorectal Cancer - Drug Profile
    varlitinib - Drug Profile
    YQ-23 - Drug Profile
    Esophageal Cancer - Dormant Projects
    Esophageal Cancer - Discontinued Products
    Esophageal Cancer - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Esophageal Cancer, H2 2016
    Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Development by Companies, H2 2016 (Contd..3)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Products under Development by Companies, H2 2016 (Contd..4)
    Products under Investigation by Universities/Institutes, H2 2016
    Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
    Esophageal Cancer - Pipeline by Advaxis, Inc., H2 2016
    Esophageal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016
    Esophageal Cancer - Pipeline by Almac Discovery Limited, H2 2016
    Esophageal Cancer - Pipeline by Amgen Inc., H2 2016
    Esophageal Cancer - Pipeline by ArQule, Inc., H2 2016
    Esophageal Cancer - Pipeline by Array BioPharma Inc., H2 2016
    Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2016
    Esophageal Cancer - Pipeline by ATLAB Pharma SAS, H2 2016
    Esophageal Cancer - Pipeline by Bayer AG, H2 2016
    Esophageal Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016
    Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
    Esophageal Cancer - Pipeline by Celgene Corporation, H2 2016
    Esophageal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016
    Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2016
    Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016
    Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016
    Esophageal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
    Esophageal Cancer - Pipeline by Genmab A/S, H2 2016
    Esophageal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
    Esophageal Cancer - Pipeline by Glycotope GmbH, H2 2016
    Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016
    Esophageal Cancer - Pipeline by Ignyta, Inc., H2 2016
    Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H2 2016
    Esophageal Cancer - Pipeline by Immunomedics, Inc., H2 2016
    Esophageal Cancer - Pipeline by Johnson & Johnson, H2 2016
    Esophageal Cancer - Pipeline by Komipharm International Co., Ltd., H2 2016
    Esophageal Cancer - Pipeline by MacroGenics, Inc., H2 2016
    Esophageal Cancer - Pipeline by MaxiVAX SA, H2 2016
    Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2016
    Esophageal Cancer - Pipeline by MedImmune, LLC, H2 2016
    Esophageal Cancer - Pipeline by Merck & Co., Inc., H2 2016
    Esophageal Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016
    Esophageal Cancer - Pipeline by Novartis AG, H2 2016
    Esophageal Cancer - Pipeline by Omeros Corporation, H2 2016
    Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2016
    Esophageal Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016
    Esophageal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
    Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
    Esophageal Cancer - Pipeline by Pfizer Inc., H2 2016
    Esophageal Cancer - Pipeline by Proteo, Inc., H2 2016
    Esophageal Cancer - Pipeline by Puma Biotechnology, Inc., H2 2016
    Esophageal Cancer - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
    Esophageal Cancer - Pipeline by Shionogi & Co., Ltd., H2 2016
    Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
    Esophageal Cancer - Pipeline by Symphogen A/S, H2 2016
    Esophageal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
    Esophageal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
    Esophageal Cancer - Pipeline by Takara Bio Inc., H2 2016
    Esophageal Cancer - Pipeline by Transgene Biotek Limited, H2 2016
    Esophageal Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016
    Esophageal Cancer - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Esophageal Cancer - Dormant Projects, H2 2016
    Esophageal Cancer - Dormant Projects (Contd..1), H2 2016
    Esophageal Cancer - Dormant Projects (Contd..2), H2 2016
    Esophageal Cancer - Dormant Projects (Contd..3), H2 2016
    Esophageal Cancer - Dormant Projects (Contd..4), H2 2016
    Esophageal Cancer - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Esophageal Cancer, H2 2016
    Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Top 10 Routes of Administration, H2 2016
    Number of Products by Stage and Top 10 Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report